Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza(Princess Margaret Cancer Centre), David Cibula(General University Hospital in Prague), Ana Oaknin Benzaquen(Vall d'Hebron Hospital Universitari), Christopher Poole(University Hospitals Coventry and Warwickshire NHS Trust), Ron H.J. Mathijssen(Erasmus MC Cancer Institute), Gabe S. Sonke(Dutch Cancer Society), Nicoletta Colombo(University of Milan), Jiří Špaček(University Hospital Hradec Králové), Peter Vuylsteke(Queen Elisabeth Medical Foundation), Holger W. Hirte(Juravinski Cancer Centre), Sven Mahner(Universität Hamburg), Marie Plante(Université Laval), Barbara Schmalfeldt(Technical University of Munich), Helen Mackay(Princess Margaret Cancer Centre), Jacqui Rowbottom(AstraZeneca (United Kingdom)), Elizabeth Lowe(AstraZeneca (United States)), Brian Dougherty(AstraZeneca (United States)), J. Carl Barrett(AstraZeneca (United States)), Michael Friedländer(UNSW Sydney)
The Lancet Oncology
December 3, 2014
Cited by 543

Abstract


Related Papers

No related papers found

Powered by citation graph analysis